Dr. Chipollini is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3838 N Campbell Ave
Tucson, AZ 85719Phone+1 520-694-4032
Summary
- Juan Chipollini, MD, FACS is an urologic oncologist and associate professor in the Department of Urology. He completed residency at the University of Miami Miller School of Medicine and went to H. Lee Moffitt Cancer Center for a Society of Urologic Oncology fellowship where he specialized in the management of urologic malignancies using both complex open and minimally-invasive surgery. Dr. Chipollini is board-certified by the American Board of Urology. He has research interests involving novel biomarkers in urothelial carcinoma. He also studies heath disparities in the treatment of urologic cancer patients. He has an active surgical practice and is principal investigator in several clinical trials at the University of Arizona.
Education & Training
H. Lee Moffitt Cancer Center and Research InstituteFellowship, Urologic Surgical Oncology, 2016 - 2018
University of Miami/Jackson Health SystemResidency, Urology, 2012 - 2016- University of Miami/Jackson Health SystemResidency, Surgery, 2011 - 2012
University of Arkansas For Medical Sciences College of MedicineClass of 2011
Certifications & Licensure
AZ State Medical License 2017 - 2025- American Board of Urology Urology
Awards, Honors, & Recognition
- Inductee Alpha Omega Alpha Honor Medical Society, 2011
Clinical Trials
- Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer Start of enrollment: 2018 Sep 24
- Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland Start of enrollment: 2021 Jul 23
- Study to Determine Possible Effects of Apalutamide on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer Start of enrollment: 2024 Jun 15
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- 28 citationsEpidemiological Assessment of Hypospadias by Degree of SeverityStephen Canon, Bridget S. Mosley, Juan Chipollini, Jody Ann Purifoy, Charlotte A. Hobbs
The Journal of Urology. 2012-12-01 - 22 citationsRacial/ethnic disparities in renal cell carcinoma: Increased risk of early-onset and variation in histologic subtypesKen Batai, Alfredo Harb De la Rosa, Jiping Zeng, Juan Chipollini, Francine C. Gachupin
Cancer Medicine. 2019-09-11 - 25 citationsMP72-06 MULTI-INSTITUTIONAL SURVIVAL ANALYSIS OF INCIDENTAL PATHOLOGIC T3A UPSTAGING IN CLINICAL T1 RENAL CELL CARCINOMA FOLLOWING PARTIAL NEPHRECTOMYChristopher M. Russell, Amir H. Lebastchi, Juan Chipollini, Adam C. Niemann, Rohit Mehra
Urology. 2017-04-01
Press Mentions
Cytoreductive Surgery May Have a Role in Treating Metastatic UTUCFebruary 1st, 2021- Identifying an Optimal Lymph Node Yield for Penile Squamous Cell Carcinoma: Prognostic Impact of Surgical Dissection - Beyond the AbstractNovember 25th, 2019
Mutational Characteristics of Chemotherapy-Treated Bladder Urothelial NeoplasmsDecember 23rd, 2016
Professional Memberships
- Member
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
